Adjunct Professor of Psychiatry University of California San Diego
Psychiatry
Dr. Stephen M. Stahl, MD
|
|
Give Review
Doctor Stephen M. Stahl, MD is an expert in the field of Psychiatry. He went to medical school at Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine is ranked 19/29 in Research/PrimaryCare. He over the years received 1 awards: "Super Doctor". Stephen Stahl is also published. He has 100 publications published. The lastest publication: "A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature.'
Publications
- A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature.
- Forensic focused treatment planning: a new standard for forensic mental health systems.
- A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-re...
- Pharmacotherapy of cognitive deficits in schizophrenia.
- Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from...
- Novel agents in development for the treatment of depression.
- A proposal for an updated neuropsychopharmacological nomenclature.
- Translating from neuroscience to psychiatry (and back translating from psychiatry to neuroscience).
- Controversies in treating bipolar depression.
- Serotonergic drugs for depression and beyond.
- The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?
- The last Diagnostic and Statistical Manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses.
- "Meta-guidelines" for the management of patients with schizophrenia.
- Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extens...
- Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.
- Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression.
- Psychotherapy as an epigenetic 'drug': psychiatric therapeutics target symptoms linked to malfunctioning brain circuits with psychotherapy as well as with drugs.
- CNS Spectrums: a new publisher, a new editor-in-chief, and new vistas.
- Practical guide for prescribing MAOIs: debunking myths and removing barriers.
- Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled tr...
- The Mechanism of Drug-induced Akathsia.
- Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder.
- The serotonin-7 receptor as a novel therapeutic target.
- Illustrating the circuits of sexual desire.
- Play it Again: The Master Psychopharmacology Program as an Example of Interval Learning in Bite-Sized Portions.
- A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus halop...
- Targeting circuits of sexual desire as a treatment strategy for hypoactive sexual desire disorder.
- Psychiatric stress testing: novel strategy for translational psychopharmacology.
- Fooling mother nature: epigenetics and novel treatments for psychiatric disorders.
- Circuits of sexual desire in hypoactive sexual desire disorder.
- Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
- Methylated spirits: epigenetic hypotheses of psychiatric disorders.
- Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms.
- Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment.
- Mechanism of action of stimulants in attention-deficit/hyperactivity disorder.
- Crisis in army psychopharmacology and mental health care at Fort Hood.
- Clinical management of major depressive disorder.
- Combining antidepressant therapies from the initiation of treatment: a paradigm shift for major depression.
- Mechanism of action of trazodone: a multifunctional drug.
- Epigenetics and methylomics in psychiatry.
- Applying the principles of adult learning to the teaching of psychopharmacology: audience response systems.
- The prefrontal cortex is out of tune in attention-deficit/hyperactivity disorder.
- Applying the principles of adult learning to the teaching of psychopharmacology: storyboarding a presentation and the rule of small multiples.
- Norepinephrine and dopamine regulate signals and noise in the prefrontal cortex.
- Applying the principles of adult learning to the teaching of psychopharmacology: overview and finding the focus.
- Vasomotor symptoms and depression in women, part 2. Treatments that cause remission and prevent relapses of major depressive episodes overlap with treatments for vasom...
- Multifunctional drugs: a novel concept for psychopharmacology.
- Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia.
- Vasomotor symptoms and depression in women, part I. Role of vasomotor symptoms in signaling the onset or relapse of a major depressive episode.
- Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines.
- The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition?
- Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants.
- L-methylfolate: a vitamin for your monoamines.
- Tailoring treatment of depression for women across the reproductive lifecycle: the importance of pregnancy, vasomotor symptoms, and other estrogen-related events in ps...
- Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a...
- The potential role of a corticotropin-releasing factor receptor-1 antagonist in psychiatric disorders.
- Dosing atypical antipsychotics.
- Do dopamine partial agonists have partial efficacy as antipsychotics?
- Personalized medicine, pharmacogenomics, and the practice of psychiatry: on the threshold of predictive therapeutics in psychopharmacology?
- Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.
- Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent.
- Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER.
- The genetics of schizophrenia converge upon the NMDA glutamate receptor.
- Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors.
- Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia.
- Overview of trends in modern psychopharmacology.
- Temperature regulation in depression: functional 5HT1A receptor adaptation differentiates antidepressant response.
- High-cost use of second-generation antipsychotics under California's Medicaid program.
- Finding what you are not looking for: strategies for developing novel treatments in psychiatry.
- SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.
- Antidepressant treatment of psychotic major depression: potential role of the sigma receptor.
- Toward convergence in the medication treatment of bipolar disorder and schizophrenia.
- 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.
- Is psychopharmacologic "inoculation" effective in preventing posttraumatic stress disorder?
- Preemptive analgesia: is pain less costly when you pre-pay for it?
- Risperidone and paroxetine given singly and in combination for bipolar depression.
- Prophylactic antipsychotics: do they keep you from catching schizophrenia?
- Atypical antipsychotics: matching receptor profile to individual patient's clinical profile.
- Drug combinations for bipolar spectrum disorders: evidence-based prescribing or prescribing-based evidence?
- Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator.
- The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication.
- Mechanism of action of alpha2delta ligands: voltage sensitive calcium channel (VSCC) modulators.
- Mechanism of action of voltage sensitive sodium channel modulators.
- Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels.
- Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels.
- Anticonvulsants as anxiolytics, part 2: Pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels.
- Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA.
- Psychopharmacology of anticonvulsants: do all anticonvulsants have the same mechanism of action?
- A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor.
- Symptoms and circuits, part 3: schizophrenia.
- Brainstorms: symptoms and circuits, part 2: anxiety disorders.
- Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.
- Symptoms and circuits, part 1: major depressive disorder.
- Deconstructing psychiatric disorders, part 2: An emerging, neurobiologically based therapeutic strategy for the modern psychopharmacologist.
- Deconstructing psychiatric disorders, Part 1. Genotypes, symptom phenotypes, and endophenotypes.
- Here today and not gone tomorrow: the curse of chronic pain and other central sensitization syndromes.
- Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes.
- The ups and downs of novel antiemetic drugs, part 2: an illustration.
- The ups and downs of novel antiemetic drugs, part 1: substance P, 5-HT, and the neuropharmacology of vomiting.
Schools
Northwestern Center Feinberg School of Medicine
Doctors Specialties
- Psychiatry
Accepted Insurances
Awards
- Super Doctor
Education
-
Stanford University -
UCSF -
University of Chicago -
Northwestern University Feinberg School of Medicine
Drug Facts
| NPI NUMBER | 1104882760 | |
| NPPES Provider LastName | STAHL | |
| NPPES Provider FirstName | STEPHEN | |
| NPPES Provider ZIPCode | 853017405 | |
| NPPES Provider State | AZ | |
| Specialty Description | Optometry | |
| Total Claim Count | 622.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1104882760 |
| Last Name Of The Provider | STAHL |
| First Name Of The Provider | STEPHEN |
| View All |
Similar Doctors
|
|
Dr. Mary Wake, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander A. Shester, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Christine Saroian, MD |
|
|
Dr. Stephen V. Sobel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley A. Terman, MD |
|
|
Dr. Beth A. Teegarden, DO |
|
|
Dr. Fortuna Israel, MD |
|
|
Dr. Mason M. Yamashita, MD |
|
|
Andrew Dickman, MA |